Clinical review report. indication: moderate-to-severe atopic dermatitis (AD). Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.) :
The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab (Dupixent) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those the...
Saved in:
| Format: | Electronic eBook |
|---|---|
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
July 2018.
|
| Series: | Common drug review clinical review report.
|
| Subjects: | |
| Online Access: | Full text |